Salix Pharma Buys Rights to Olon's IP Related to Amorphous Rifaximin

Salix Pharmaceuticals, Ltd.

today announced that as of May 30, 2013, it had purchased from Olon S.p.A. (formerly Solmag) a pending patent application claiming amorphous rifaximin and an issued patent that Olon recently acquired from Apotex Pharmachem, Inc. claiming amorphous rifaximin, together with related intellectual property rights. Additionally, Olon granted Salix the exclusive worldwide right under Olon's intellectual property rights to exploit amorphous rifaximin.